SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Sabine Haggenburg; Quincy Hofsink; Caroline E. Rutten; Inger S. Nijhof; Mette D. Hazenberg; Abraham Goorhuis

doi:https://doi.org/10.1053/j.seminhematol.2022.11.001

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Sabine Haggenburg, Quincy Hofsink, Caroline E. Rutten, Inger S. Nijhof, Mette D. Hazenberg, Abraham Goorhuis

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.

Original language	English
Pages (from-to)	192-197
Journal	Seminars in Hematology
Volume	59
Issue number	4
Early online date	2022
DOIs	https://doi.org/10.1053/j.seminhematol.2022.11.001
Publication status	Published - 2022

Keywords

COVID-19
Hematologic malignancies
Hematology
Immunocompromised
SARS-CoV-2
Vaccination

Access to Document

https://doi.org/10.1053/j.seminhematol.2022.11.001

Cite this

@article{cba355eaea6848f18c3ee631b840b39b,

title = "SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies",

abstract = "Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.",

keywords = "COVID-19, Hematologic malignancies, Hematology, Immunocompromised, SARS-CoV-2, Vaccination",

author = "Sabine Haggenburg and Quincy Hofsink and Rutten, {Caroline E.} and Nijhof, {Inger S.} and Hazenberg, {Mette D.} and Abraham Goorhuis",

note = "Funding Information: We would like to acknowledge all patients who participated in the COBRA-KAI study, all collaborating centers (LUMC, UMCG, Erasmus MC), the Netherlands Comprehensive Cancer registration (IKNL), and the Dutch National Institute for Public Health and the Environment (RIVM). The COBRA-KAI study is funded by ZonMW. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

doi = "https://doi.org/10.1053/j.seminhematol.2022.11.001",

language = "English",

volume = "59",

pages = "192--197",

journal = "Seminars in Hematology",

issn = "0037-1963",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

AU - Haggenburg, Sabine

AU - Hofsink, Quincy

AU - Rutten, Caroline E.

AU - Nijhof, Inger S.

AU - Hazenberg, Mette D.

AU - Goorhuis, Abraham

N1 - Funding Information: We would like to acknowledge all patients who participated in the COBRA-KAI study, all collaborating centers (LUMC, UMCG, Erasmus MC), the Netherlands Comprehensive Cancer registration (IKNL), and the Dutch National Institute for Public Health and the Environment (RIVM). The COBRA-KAI study is funded by ZonMW. Publisher Copyright: © 2022 The Author(s)

PY - 2022

Y1 - 2022

N2 - Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.

AB - Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.

KW - COVID-19

KW - Hematologic malignancies

KW - Hematology

KW - Immunocompromised

KW - SARS-CoV-2

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85143270820&partnerID=8YFLogxK

U2 - https://doi.org/10.1053/j.seminhematol.2022.11.001

DO - https://doi.org/10.1053/j.seminhematol.2022.11.001

M3 - Article

C2 - 36805887

SN - 0037-1963

VL - 59

SP - 192

EP - 197

JO - Seminars in Hematology

JF - Seminars in Hematology

IS - 4

ER -

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Abstract

Keywords

Access to Document

Other files and links

Cite this